Redeye comments on Freemelt ahead of its Q2 results, due on 6 August.
- Slight quarterly miss on operating lines is a non-event - Acquisition potential remains, '25e CEPS...
- Q2 due Thursday, 18 July, 08:30 CET - We expect lukewarm orders, but a continued high gross margin...
Redeye provides its initial comments on Nanologica following its Q2 report that showed softer sales ...
Ahead of Svedbergs Group's Q2 report on 18 July, we expect a decent quarter, with a 1% organic sales...
Q2e: Positive margin trends and cash flow We expect Q2 sales of EUR 42.
Q2e: limited developments In Q2, we expect SEK 279m in order intake, down 2% y-o-y, and sales of SEK...
Redeye comments on the final outcome of Modelon’s rights issue, giving the company SEK50.
Cultural and customer similarities bode well Prevas has received regulatory clearance for its acquis...
Rec PTP -7% vs ABGSCe, -8% y-o-y Fastpartner delivered a Q2 report with rental income of SEK 574m (-...
Solwers’ subsidiary Davidsson Tarkela Architects Oy has today signed an agreement to acquire 100% of...
Reasons to be optimistic after slow start to the year We expect Elanders to report Q2 net sales of S...
AAC Clyde Space has announced the acquisition of Spacemetric for a total consideration of SEK25m (in...
Yesterday after close Acarix announced a SEK21m directed share issue targeting US based family offic...
Redeye comments on the directed share issue, new cooperation with Presto, and the subsequent initial...
Duell’s Q3 development was two-fold as growth in Europe was stronger than expected while revenue dec...
Redeye comments on the Paxman contract with the US Veterans Association as a sole contractor with th...
Redeye comments on AVTECH’s key figures, which came in 5% ahead on net sales and 25% on EBITDA, sugg...
Redeye endorses SenzaGen’s continued collaboration with RIFM.
Redeye presents its preview for Devyser Diagnostics’ Q2 2024 report, due on July 23.